Archives
-
5-(N,N-dimethyl)-Amiloride in Endothelial Assays
2026-09-17
5-(N,N-dimethyl)-Amiloride hydrochloride is a selective Na+/H+ exchanger probe for dissecting intracellular pH regulation, sodium flux, and endothelial barrier phenotypes. This article connects its transporter pharmacology with the moesin-centered sepsis model while defining practical assay boundaries and interpretation strategies.
-
Ruxolitinib phosphate: JAK/STAT Assay Guide
2026-09-17
Ruxolitinib phosphate (INCB018424) provides a practical way to connect JAK1/2 inhibition with STAT3, mitochondrial dynamics, apoptosis, and pyroptosis readouts. This workflow translates evidence from anaplastic thyroid carcinoma into reproducible assay design while clarifying how the compound can support rheumatoid arthritis research and autoimmune disease models.
-
Tunable Human Intestinal Organoids: Study Insights
2026-09-16
Yang and colleagues developed a human small intestinal organoid system that maintains strong proliferation while expanding epithelial cell diversity under a single culture condition. The study shows that coordinated pathway modulation can reversibly or directionally shift lineage output, providing a practical framework for organoid expansion, differentiation, and high-throughput research.
-
Triamcinolone B1859: Practical Research Guide
2026-09-16
Triamcinolone B1859 is a synthetic glucocorticoid agonist for controlled research on glucocorticoid receptor signaling, inflammation, and immunosuppression. This guide addresses solvent selection, stock preparation, storage, controls, and assay QC; the compound is for scientific research only and should not be used for diagnostic, therapeutic, or clinical applications.
-
LY294002 Workflows for PI3K Signaling Studies
2026-09-15
Learn how to use LY294002 to resolve PI3K/Akt/mTOR pathway activity, apoptosis, autophagy, and cardiomyocyte injury in time-controlled experiments. The workflow combines pharmacological inhibition with the miR-24-3p/Sp1/PI3K findings from a doxorubicin-induced heart failure study while clearly addressing selectivity and assay-design limits.
-
VE-821: ATR Kinase Inhibitor for DDR Research
2026-09-15
VE-821 is a selective, ATP-competitive ATR kinase inhibitor for DNA damage response and DNA repair pathway research. It inhibits ATR–Chk1 signaling, supports radiosensitization assay design, and provides a bounded tool for testing chemotherapy sensitization hypotheses.
-
MG-132: Proteostasis Logic for HCMV Assays
2026-09-14
MG-132 and Z-LLL-al can do more than trigger apoptosis: they can help researchers test whether viral regulation of MyD88 reflects proteasome-linked protein turnover or a secondary stress response. This article translates recent HCMV findings into a cautious, mechanistically resolved assay strategy.
-
Ceftolozane/Tazobactam: Mechanism and Evidence
2026-09-14
This review examines how ceftolozane/tazobactam combines a PBP-focused cephalosporin with β-lactamase inhibition to address resistant Gram-negative pathogens. Its value lies in integrating structural pharmacology, susceptibility data, pharmacokinetics, pharmacodynamics, animal evidence, clinical trials, and safety findings into a translational framework.
-
DiI (DiIC18(3)) Membrane Probe Guide
2026-09-13
DiI (DiIC18(3)) is a lipophilic orange fluorescent probe for labeling plasma membranes in live or fixed cells and tissues, supporting neuronal tracing, migration, adhesion, fusion, and lipoprotein workflows. It is not suitable for water-based staining, and detergents or unsuitable solvent handling can reduce membrane localization and affect cell viability.
-
Mecamylamine Hydrochloride in Gut–Brain Assays
2026-09-12
Mecamylamine hydrochloride is a blood-brain barrier-permeable, non-competitive nAChR antagonist for testing cholinergic causality. This article translates recent gut–brain seizure findings into a practical assay framework while defining what broad nicotinic blockade can—and cannot—prove.
-
GCXX Protects Against 5-FU Intestinal Mucositis
2026-09-11
A 2026 study reports that Gancao Xiexin decoction reduces 5-fluorouracil-induced intestinal mucositis in mice by limiting ferroptosis through ACSL4 suppression and Keap1-Nrf2 pathway activation. Its integrated histological, biochemical, pathway, and target-engagement analyses provide a preclinical framework for studying chemotherapy-associated intestinal injury, while the findings still require validation in controlled mechanistic and clinical models.
-
DiI (DiIC18(3)) Plasma Membrane Probe Guide
2026-09-11
DiI (DiIC18(3)) is a lipophilic orange fluorescent membrane dye for labeling plasma membranes in live or fixed biological samples, supporting neuronal tracing, migration studies, and membrane-associated assays. It is not suitable for aqueous-only staining, exclusive cytoplasmic labeling, or organelle-specific targeting, and solvent handling is essential for reproducible localization.
-
Annular Sector Microneedles for Glaucoma Therapy
2026-09-10
Huang and colleagues developed an annular sector-shaped microneedle patch to deliver an Nmnat1 gene formulation and nicotinamide directly to the trabecular meshwork. The combined treatment improved mitochondrial support in human trabecular meshwork cells and reduced intraocular pressure and fibrosis in a dexamethasone-induced mouse model, providing a localized strategy for addressing glaucoma-associated tissue dysfunction.
-
Cy7 NHS ester: Practical Labeling and QC Guide
2026-09-10
Cy7 NHS ester (SKU A8109) is a water-soluble, sulfonated near-infrared dye for labeling accessible amino groups on proteins, peptides, and related biomolecules. It is useful when aqueous handling and near-infrared fluorescent imaging are priorities, but this guide does not substitute for target-specific optimization or validation, and no directly matched paper evidence is used.
-
3-Bromopyruvate Overcomes Cetuximab Resistance in CRC
2026-09-09
Mu and colleagues show that combining 3-bromopyruvate with cetuximab can restore drug sensitivity in colorectal cancer models with intrinsic or acquired cetuximab resistance. The study links this effect to FOXO3a-dependent activation of autophagy, ferroptosis, and apoptosis, providing a mechanistic framework for investigating resistant tumors.